You are here:
The free movement of medicines was greatly increased as a result of regulations on medicines introduced by the European Union and the granting of marketing authorisations with validity in all member states of the European Economic Area. This made it even more important to reconsider the methods for the analytical supervision of licensed medicines, which was previously carried out by individual national authorities. Consequently, a co-ordinated European approach to controlling medicines (the OMCL network) was set up. For more information about the Network’s mission, please see our website.